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http://dx.doi.org/10.1016/j.jfma.201Background/Purpose: In order to know the true incidence of severe combined immunodefi-
ciency (SCID) in a Chinese population, we conducted and implemented SCID newborn screening
in Taiwan.
Methods: Between May 1, 2010 and December 31, 2011, the National Taiwan University
Hospital Newborn Screening Center screened all newborns for T-cell lymphopenia by
measuring the copy number of T-cell receptor excision circles (TRECs) and RNase P. Newborns
with low TREC values were subjected to complete blood cell counts and flow cytometry.
Results: A total of 106,391 newborns were screened using the TREC assay over a period of 19
months. Five newborns were immediately referred for confirmatory tests, including two SCID
patients and two patients with persistent T-cell lymphopenia; a third SCID patient was found 2
months after the study period. All three SCID cases received stem cell transplantation at the
age of 2e5 months. We also identified five cases of 22q11.2 microdeletion syndrome. During
this period, two SCID patients from among the unscreened newborns were reported, and they
died at ages 3 months and 4 months, respectively.
Conclusion: Newborn screening to measure the number of TREC copies successfully identifies
newborns with T-cell lymphopenia, 22q11.2 microdeletion syndrome, and other high-risk condi-
tions. Taken together, the incidence of T-cell lymphopenia in apparently healthy newborns is
more than 1 in 11,821, and further attention to their immune functions is warranted.
Copyright ª 2012, Elsevier Taiwan LLC & Formosan Medical Association. All rights reserved.of Medical Genetics, National Taiwan University Hospital, Taipei, Taiwan.
u.tw (W.-L. Hwu).
ight ª 2012, Elsevier Taiwan LLC & Formosan Medical Association. All rights reserved.
2.10.020
Incidence of SCID in Chinese newborns 13Introduction
unscreened population in Taiwan served as controls.Severe combined immunodeficiency disease (SCID) is a term
that describes a spectrum of primary immunodeficiencies
that comprise more than 16 independent genetic condi-
tions,1,2 all of which result in severe defects in cellular and
humoral immunity. Patients with SCID usually present nor-
mally at birth but then suffer from life-threatening infec-
tions and ultimately die before 1 year of age if not treated
appropriately. Hematopoietic stem cell (HSC) trans-
plantation before the onset of serious infections markedly
improves the long-term prognosis of these patients.3,4 With
proof that the T-cell receptor excision circle (TREC) assay
can detect patients with SCID and other T-cell deficiencies,
in conjunction with evidence suggesting that SCID met the
criteria for newborn screening, the Federal Secretary’s
Advisory Committee on Heritable Disorders and Genetic
Diseases in Newborns and Children of the United States
recommended in 2010 that SCID be included in the rec-
ommended uniform national newborn screening (NBS) panel
for infants in all states.
Newborns with immunodeficiency attract special atten-
tion in Taiwan. First, most patients (85%) affected by SCID
and other combined T-cell and B-cell immunodeficiencies
had symptom onset before 1 year of age and high mortality
(30%).5 Second, babies in Taiwan receive Bacille Calmette-
Gue´rin (BCG) vaccination immediately after birth. Two
cases of SCID babies who received BCG vaccination at 1 day
old have been reported.5 Additionally, BCG infection
occurred in 23.8% of infants with SCID and caused compli-
cations in 50% of patients who underwent HSC trans-
plantation.5 Although the incidence of SCID has been
reported to be low,6 this low incidence probably reflects an
underestimation rather than an ethnic difference.5 In order
to know the true incidence of SCID and related T-cell
immunodeficiency, we conducted the first SCID NBS in
Taiwan and present the results.
Materials and methods
The SCID pilot screen program was integrated into the
regular screening program of the National Taiwan Univer-
sity Hospital (NTUH) Newborn Screening Center, which0%
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Figure 1 Distribution of T-cell receptor excision circle (TREC) va
the low TREC value ranges.routinely screens 35e37% of newborns in Taiwan. The
Parental consent was obtained for each newborn to allow
the newborn screening card to be used for the TREC assay.
The Institutional Review Board (IRB) of the hospital
approved this pilot program. The screening is now ongoing
on a self-paid base, and is provided to all babies born in
Taiwan including those screened by other screening
centers.
The TREC assay was performed as previously described7
with slight modifications, namely the elution volume and
the volume for real-time quantitative PCR (RT-PCR).
Briefly, one 3.2-mm paper disk was punched from the dried
blood spot (DBS) newborn card. DNA was then extracted
from the paper disk (by Generation DNA Purif. Solution and
Generation DNA Elution Solution, QIAGEN), and RT-qPCR
was performed to estimate the values for the TREC assay
and RNase P (by TaqMan Gene Expression Master Mix,
Applied Biosystems). The TREC value was normalized to
microliters of whole blood based on the estimation that
each 3.2-mm paper disk contains 3 mL of whole blood. The
cutoff value for the TREC assay was <40 TRECs/mL, as
the revised cutoff in the original program.8 The value for
RNase P served as a control for sample integrity and blood
quantity. A DBS with a zero TREC value but a normal RNase
P value was defined as abnormal. A DBS with a TREC value
between zero and 40 was defined as inconclusive. All
inconclusive DBSs required a repeat DBS, and either a low
or zero TREC value on the repeat DBS was defined as
abnormal. Newborns with abnormal SCID screening
required a whole blood sampling so that a complete blood
count and flow cytometry could be performed to confirm
the SCID diagnosis. For a DBS with an abnormal or incon-
clusive screening result, TUPLE1 gene copy number analysis
for chromosome 22q11.2 microdeletion syndrome9 was
performed.Results
The screening performance
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lues in newborns. (A) Overall distribution. (B) Distribution over
14 Y.-H. Chien et al.is shown in Fig. 1. The mean TREC value was 283/mL, and
the median was 202/mL. From analyzing the data with low
TREC value ranges (Fig. 1B), our cutoff was set at 40 TRECs/
mL, because there was only very few newborns with values
lower than 40 TRECs/mL. Among the 106,391 newborns,
97044 (91.2%) were full-term, and 8382 (7.9%) were
preterm. SCID screening was abnormal (a zero TREC value)
in five newborns and was inconclusive in 262 full-term
newborns (0.27%) and 110 preterm newborns (1.31%).
Approximately 0.4% of all newborns required a repeat NBS,
and among these, 19 had abnormal results (Fig. 2).
Newborns with persistent T-cell lymphopenia
Four of the five newborns who had a zero TREC value from
the first DBS were found to have persistent T-cell lympho-
penia and were classified as SCID or SCID variants according
to the IL-A/36 Clinical Laboratory Standards Institute (CLSI)
Document on Newborn screening for Severe Combined
Immunodeficiency (document in preparation, December 8,
2011)10 and Expert Commentary11 (Table 1). The fifth
newborn had chylothorax, which explained the reason for
abnormal SCID screening. The two SCID patients each had
IL2RG (Patient 1) and RAG1 (Patient 2) gene mutations, and
mis-matched cord blood stem cell transplantations were
performed at the age of 2.8 months and 5.3 months,
respectively.
For the two cases of idiopathic T-cell lymphopenia
identified by our newborn screening program, Patient 3 had
normal B-cell counts and an increased number of natural
killer cells (Table 1). He also had a normal level of immu-
noglobulin G (IgG), but his mitogen stimulation test showed105 864 (99.4%) Normal 
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Figure 2 The severe combined immunodeficiency (SCID) scree
newborns under each category are also indicated.subnormal proliferation responses (15% of normal). At the
age of 15 months, he still had T-cell lymphopenia (341/mL).
Patient 4 had increased numbers of B and natural killer
cells, normal IgG, and normal mitogen stimulation test; at
the age of 5 months and 13 months, her T-cell lymphopenia
gradually improved (591/mL and 1145/mL, respectively).
Her elder brother also had T-cell lymphopenia since birth.
At 33 months of age, he had normal IgG, a normal response
to BCG vaccination, a normal level of anti-Hepatitis B
surface antibodies, and normal body weight and develop-
ment. We have exhausted mutation analyses in Patient 3
and 4 for the IL2RG, JAK3, IL7Ra, RAG1, RAG2, CD3 3/d/z
chains, and Artemis genes, but we still cannot determine
their molecular defects.
The sixth newborn (Patient 5, Table 1) who had a zero
TREC value from the first DBS was identified 2 months after
the study period, and he received related peripheral blood
stem cell transplantation from his sister at the age of 1.9
months.
Newborns with chromosome 22q11.2
microdeletion syndrome
Five newborns were found to have chromosome 22q11.2
microdeletion syndrome by TUPLE1 gene copy number
analysis. Four of these newborns were apparently healthy,
and one had a cleft palate. The genetic diagnosis was
confirmed by multiplex ligation-dependent probe amplifi-
cation (MLPA). We also found another newborn with TUPLE1
gene deletion who had inconclusive results at the first
screening. However, this case had a normal TREC result at
the second DBS, and no further information was available.5 Abnormal 
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Incidence of SCID in Chinese newborns 15Other medical conditions
Ten (41.7%) of the 24 newborns with an abnormal SCID
screening had a delay in the time of blood sampling (after 72
hours of age) for the first NBS. Among them, five suffered
from congenital heart diseases and had undergone surgery
soon after birth, one had a congenital cytomegalovirus
infection with pancytopenia, and three were extremely low-
birth weight. Two newborns who underwent cardiac surgery
and one who was premature subsequently received intrave-
nous gamma globulin (IVIG) supplementation because of
repeated infections and low gamma globulin levels.
The unscreened population
During the study period, clinical diagnoses of another two
cases of SCID were encountered among the unscreened
newborns (around 200,000 in number). The first case had
the IL2RG gene mutation and he died of parainfluenza III
pneumonia at 4 months of age. The second case died at 3
months of age without a molecular diagnosis. Retrieving
their first DBS showed a zero TREC value, indicating the
possibility to detect them if NBS had been performed.
Discussion
In this article, we report the incidence of SCID from the first
SCID NBS program in Taiwan. Twenty-four infants from a total
of 106,391 newborns underwent confirmatory analysis
subsequent to the TREC assay that was added to the standard
NBS, and we confirmed low T-lymphocyte numbers in 18 of
these cases. We discovered four cases of persistent T-cell
lymphopenia, five cases of chromosome 22q11.2 micro-
deletion syndrome, and several other high-risk conditions,
including cardiac surgery that may be associated with immu-
nologic problems in newborns. Taken together, the incidence
of T-cell lymphopenia in apparently healthy newborns ismore
than one in 11,821. The early diagnosis of these 22q11.2
microdeletion syndrome patients may prevent subsequent
complications associated with hypocalcemia or immunodefi-
ciency. Although it is known that lowTRECvaluesmayoccur in
newborns after cardiac surgery, we still need to be careful
because it is sometimes associated with low immunoglobulin
levels. Appropriate management such as the administration
of IVIG may decrease the risk of infection in these newborns.
After screening 106,391 newborns, we encountered two
cases of SCID. Therefore, the incidence of SCID is estimated
to be one in 53,196. During the same period, two SCID
patients from among the unscreened newborns were re-
ported. This incidence is higher than previous clinical
observations.6 In the current study, we also detected a high
incidence of 22q11.2 microdeletion syndrome. It has been
reported that the TREC assay sometimes can detect other
T- and B-cell anomalies, such as the hyper IgE syndrome12
and anhidrotic ectodermal dysplasia with immunodefi-
ciency (personal experience), which confirms the power of
the TREC assay as a screening tool. The performance and
results of our SCID screening program are similar to other
pilot programs,11 which detected 14 SCID cases among
961,925 newborns (1 in 68,000) and another 60 newborns (1
in 16,032) with other forms of immune deficiency, and no
16 Y.-H. Chien et al.missed cases have come to their attention. The cost of our
screening program, 5 USD per assay, is also similar to that of
other programs.
At this point, we have not identified the molecular
defects of the two newborns with idiopathic T-cell lym-
phopenia. Similar experiences with symptomatic primary
immunodeficiency have been reported.5,13 Since SCID has
been implemented into the routine NBS program, in the
future presymptomatic diagnosis of SCID and atypical SCID
will increase. In patients with SCID-related gene mutations,
some of them could have normal T-cell counts or normal
IgG, although most patients had severe infectious diseases
before the diagnosis was established.14 However, molecular
confirmatory tests for primary immunodeficiency are
sometimes problematic,5,8,13 and the decision to undertake
HSC transplantation for patients with hypomorphic or novel
mutations could be difficult. Nevertheless, the imple-
mentation of SCID newborn screening will certainly trigger
more research on immunodeficiencies in the future.
In conclusion, measuring the number of TREC copies as
a part of NBS successfully identifies newborns with T-cell
lymphopenia, 22q11.2 microdeletion syndrome, and other
high-risk conditions, and therefore, it should be conducted
universally in Taiwan. Taken together, the incidence of
T-cell lymphopenia in apparently healthy newborns is more
than one in 11,821, and further attention to their immune
health is warranted.Acknowledgments
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